Tracleer is a drug owned by Actelion Pharmaceuticals Us Inc. It is protected by 3 US drug patents filed from 2013 to 2017. Out of these, 2 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 28, 2027. Details of Tracleer's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7959945 | Dispersible bosentan tablet |
Dec, 2027
(2 years from now) | Active |
| US8309126 | Dispersible bosentan tablet |
May, 2026
(6 months from now) | Active |
| US5292740 | Sulfonamides |
Nov, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Tracleer's patents.
Latest Legal Activities on Tracleer's Patents
Given below is the list of recent legal activities going on the following patents of Tracleer.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 May, 2024 | US8309126 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Nov, 2022 | US7959945 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2020 | US8309126 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Dec, 2018 | US7959945 |
| Filing Receipt - Corrected | 23 Sep, 2013 | US7959945 |
| Email Notification
Critical | 23 Sep, 2013 | US7959945 |
| Recordation of Patent Grant Mailed
Critical | 13 Nov, 2012 | US8309126 |
| Patent Issue Date Used in PTA Calculation
Critical | 13 Nov, 2012 | US8309126 |
| Issue Notification Mailed
Critical | 24 Oct, 2012 | US8309126 |
| Dispatch to FDC | 19 Oct, 2012 | US8309126 |
FDA has granted several exclusivities to Tracleer. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Tracleer, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Tracleer.
Exclusivity Information
Tracleer holds 6 exclusivities. All of its exclusivities have expired in 2024. Details of Tracleer's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-607) | Aug 07, 2012 |
| New Product(NP) | Sep 05, 2020 |
| New Patient Population(NPP) | Sep 05, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 05, 2024 |
| ODE*(ODE*) | Sep 05, 2024 |
| Orphan Drug Exclusivity(ODE-161) | Sep 05, 2024 |
US patents provide insights into the exclusivity only within the United States, but
Tracleer is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tracleer's family patents as well as insights into
ongoing legal events
on those patents.
Tracleer's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tracleer's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 28, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tracleer Generic API suppliers:
Bosentan is the generic name for the brand Tracleer. 11 different companies have already filed for the generic of Tracleer, with Natco Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tracleer's generic
How can I launch a generic of Tracleer before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Tracleer's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Tracleer's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Tracleer -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 32 mg | 08 Feb, 2019 | 1 | 28 Dec, 2027 |
About Tracleer
Tracleer is a drug owned by Actelion Pharmaceuticals Us Inc. Tracleer uses Bosentan as an active ingredient. Tracleer was launched by Actelion in 2017.
Approval Date:
Tracleer was approved by FDA for market use on 05 September, 2017.
Active Ingredient:
Tracleer uses Bosentan as the active ingredient. Check out other Drugs and Companies using Bosentan ingredient
Dosage:
Tracleer is available in the following dosage forms - tablet form for oral use, tablet, for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 32MG | TABLET, FOR SUSPENSION | Prescription | ORAL |
| 62.5MG | TABLET | Prescription | ORAL |
| 125MG | TABLET | Prescription | ORAL |